Novartis

After Novartis Pact, Macrocycle Shop Unnatural Products Gets $45M Series B

Novartis, SciNeuro to Work Together on Preclinical Amyloid-Targeting Drug for Alzheimer’s

Isomorphic Labs Raises $2.1 B to Expand AI-Driven Drug Discovery Platform

Keep an Eye on These 15 Biotech Companies in 2026 

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall

After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar

STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More

Novartis Breaks Ground on San Diego Biomedical R&D Site

4 Spaces Primed for the Next Wave of Gene Therapies

Biotech in 2025: A Retrospective 

UAE Exits OPEC, Iran Peace Talks Spark Mixed Moves in European Stocks

Burnout Common but Regrets Are Not in Allergy, Immunology

Celcuity’s Gedatolisib Beats Novartis’ Piqray in Phase III Advanced Breast Cancer Trial

Health Care Roundup: Market Talk

Iridius Raises $8.6M Seed Round to Build Compliance-by-Design AI Platform for Regulated Enterprise Workflows

Vertex Secures German Reimbursement Deal for CASGEVY Gene Therapy

STAT+: Novartis CEO Joins Anthropic’s Board

TerraPower Commits $450M to Build Radioisotope Production Plant

Incyte Gobbles up Star's Vega Haematology Unit in $2bn Deal

Anti-Amyloid Alzheimer’s Drugs Show Limited Benefit in Cochrane Review

Novartis Licenses Radiopharma Asset From Chinese Biotech for $50M Upfront

Telix, Regeneron Ink $40M 50/50 Deal to Co‑Develop Next‑Gen Radiopharmaceuticals

FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna)

GSK Reports Promising Early Results in Ovarian and Womb Cancer Drug Trial

Alphabet's Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Discovery Toward Clinical Trials

Fulcrum Exploring a Potential Sale After FDA Sidelined Its Sickle Cell Drug

This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster

AstraZeneca Leads Big Pharma’s AI Clinical Trials Revolution with Real-World Patient Impact

Novartis Reveals More Data Behind Pluvicto Expansion Bid

Uber Eats Scoops US Grand Effie

NVP-INE963

Novartis Slashes 114 More Jobs at New Jersey HQ

Navigating the Perilous Journey From Lab to Market

FDA Week Highlights: Philips AI Ultrasound Clears, KMDA Approved, Multiple Deals and Halts

Novartis' Radioligand Therapy Lutathera Could Soon Face Generic Competition

Fragment Merging – and Flipping – on the Leucine Zipper of MITF

Orion Properties Leases Full Irving Office Building: The DFW Deal Sheet

Novartis to Buy US-Based Biotech Firm Excellergy for up to US$2 Billion

Niowave, Fresh From Novartis Deal, Starts Building $75M Radioisotope Plant

White House Announces Expansion of TrumpRx.gov

Celcuity Breast Cancer Drug Misses ‘Lofty’ Expectations in ASCO-Spotlighted Trial

Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100

FDA Approves Incyte’s Once‑Daily Jakafi XR for Myelofibrosis, Polycythemia Vera and GVHD

Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies

Insufficient Source Data to Report on Novartis‑Excellergy Deal

Novartis CEO Joins Board of "Responsible" AI Firm Anthropic

The Company that Built TikTok’s Algorithm Is Now Designing Drugs for Diseases Pharma Called Undruggable

Trump’s New Drug Advertising Proposals Fall Short on Public Health and the Constitution

Will New Reforms Fix the ‘Fundamentally Broken’ PBM System?

Novartis Signs $1.44B Multi-Year Collaboration with Orionis Biosciences

Novartis to Acquire Experimental Breast Cancer Drug From Synnovation Therapeutics for $2B

Novartis to Acquire Avidity Biosciences in $12B Takeover

Novartis to Sell 70.68% Stake in Novartis India to Consortium for ₹1,446 Crore

Unnatural Products Secures $1.8B Cardio Pact with Novartis